In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chelsea Therapeutics International Ltd.

Division of H. Lundbeck AS
www.chelseatherapeutics.com

Latest From Chelsea Therapeutics International Ltd.

The 'Dead Cat' Strikes Back: What Does US FDA Do With A Challenging Panel Outcome?

Akcea’s volanesorsen for familial chylomicronemia syndrome barely made it through advisory committee due to a rare but unpredictable and rapidly presenting adverse event that likely can’t be resolved with a REMS. Now what? 
Advisory Committees Drug Safety

US Capitol Capsule: 2014: a year for orphan drugs, anti-PD-1s, 2nd chancers

The FDA's Center for Drug Evaluation and Research (CDER) in 2014 had its best year in drug approvals since 1996 – clearing 41 new molecular entities (NMEs) and novel biologics over the past 12 months.

Metabolic Disorders Cardiovascular

Danish Lundbeck’s Brexpiprazole Could Reach U.S. Market In 2015

But the CNS disease specialist also expects the continuing loss of marketing exclusivity on key products and product launch costs to hold back revenue growth and profits in 2015 that will not be fully compensated by sales from multiple new product launches around the world.

BioPharmaceutical Europe

Biopharma Dealmaking Quarterly Statistics, Q2 2014

Biopharma financing totaled $7.2 billion, a 36% decrease from Q1; 36 completed M&As had a combined potential value reaching $116 billion, more than three-and-a-half times the previous quarter; 84 biopharma alliances, together totaling $7.7 billion in potential pre-commercialization value, showed a significant jump from Q1’s $1.9 billion aggregate.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Chelsea Therapeutics Inc.
  • Aspen Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • H. Lundbeck AS
  • Senior Management
  • J. Nick Riehle, VP, Admin. & CFO
    L. Arthur Hewitt, PhD, CSO
    Michael J Roberts, PhD, VP, Bus. Dev.
    Kevin W Schmidt, Chief Commercial Officer
  • Contact Info
  • Chelsea Therapeutics International Ltd.
    Phone: (704) 341-1516
    3530 Toringdon Way
    Ste. 200
    Charlotte, NC 28277
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register